(+)-Etomoxir (sodium salt) – 50 mg

Brand:
Cayman
CAS:
828934-41-4
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

(+)-Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1 (CPT1), an enzyme that combines fatty acyl-CoAs with carnitine for transport into the mitochondria for β-oxidation.{26273,26271} It inhibits fatty acid oxidation in hepatocytes in vitro (IC50s = 0.1, 1, and 10 µM for human, guinea pig, and rat hepatocytes, respectively), and it shifts the carbon source for the TCA cycle to glucose.{46094,46095} It also inhibits cholesterol synthesis from acetate in hepatocytes upstream of mevalonate.{46096} (+)-Etomoxir also decreases ATP-linked and uncoupled oxygen consumption in C2C12 myotubes when used in combination with BPTES (Item No. 19284) or UK 5099 (Item No. 16980).{47146}  

 

Available on backorder

SKU: 11969 - 50 mg Category:

Description

An inhibitor of CPT1; inhibits fatty acid transport into the mitochondria for β-oxidation; inhibits fatty acid oxidation in hepatocytes in vitro (IC50s = 0.1, 1, and 10 µM for human, guinea pig, and rat hepatocytes, respectively); decreases ATP-linked and uncoupled oxygen consumption in C2C12 myotubes when used in combination with BPTES or UK 5099


Formal name: (2R)-2-[6-(4-chlorophenoxy)hexyl]-2-oxiranecarboxylic acid monosodium salt

Synonyms:  (R)-(+)-Etomoxir

Molecular weight: 320.7

CAS: 828934-41-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Inhibitors|Acyltransferases||Research Area|Cardiovascular System|Lipids & Lipoproteins|Cholesterol Metabolism||Research Area|Cell Biology|Mitochondrial Biology||Research Area|Lipid Biochemistry|Fatty Acids|Degradation